Neil Rabin

3.5k total citations
72 papers, 788 citations indexed

About

Neil Rabin is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Neil Rabin has authored 72 papers receiving a total of 788 indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Hematology, 37 papers in Molecular Biology and 31 papers in Oncology. Recurrent topics in Neil Rabin's work include Multiple Myeloma Research and Treatments (58 papers), Cancer Treatment and Pharmacology (18 papers) and Protein Degradation and Inhibitors (18 papers). Neil Rabin is often cited by papers focused on Multiple Myeloma Research and Treatments (58 papers), Cancer Treatment and Pharmacology (18 papers) and Protein Degradation and Inhibitors (18 papers). Neil Rabin collaborates with scholars based in United Kingdom, United States and Greece. Neil Rabin's co-authors include Kwee Yong, Amit Nathwani, Chara Kyriakou, Arnold Pizzey, Rakesh Popat, Shirley D’Sa, Charalampia Kyriakou, Ali Rismani, Magdalena Sokolska and Arash Latifoltojar and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Neil Rabin

60 papers receiving 777 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neil Rabin United Kingdom	16	409	396	321	195	83	72	788
Rita Assi United States	13	388 0.9×	230 0.6×	237 0.7×	137 0.7×	157 1.9×	49	824
Raphaël Szalat United States	19	397 1.0×	499 1.3×	267 0.8×	157 0.8×	67 0.8×	64	954
Divaya Bhutani United States	17	309 0.8×	454 1.1×	280 0.9×	142 0.7×	32 0.4×	75	815
Anna Butturini United States	17	432 1.1×	258 0.7×	301 0.9×	183 0.9×	53 0.6×	48	1.1k
Stéphanie Harel France	15	315 0.8×	316 0.8×	190 0.6×	276 1.4×	41 0.5×	51	785
Zeba N. Singh United States	15	497 1.2×	360 0.9×	485 1.5×	130 0.7×	46 0.6×	54	984
Jieun Uhm Canada	16	338 0.8×	145 0.4×	360 1.1×	182 0.9×	112 1.3×	57	876
Michel Delforge Belgium	17	716 1.8×	486 1.2×	509 1.6×	120 0.6×	29 0.3×	111	1.0k
Gavivann Veerakul Thailand	14	238 0.6×	177 0.4×	132 0.4×	163 0.8×	68 0.8×	34	744
Marc Wetterwald France	12	479 1.2×	327 0.8×	480 1.5×	132 0.7×	28 0.3×	16	869

Countries citing papers authored by Neil Rabin

Since Specialization

Citations

This map shows the geographic impact of Neil Rabin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Rabin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Rabin more than expected).

Fields of papers citing papers by Neil Rabin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Rabin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Rabin. The network helps show where Neil Rabin may publish in the future.

Co-authorship network of co-authors of Neil Rabin

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Rabin. A scholar is included among the top collaborators of Neil Rabin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Rabin. Neil Rabin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yong, Kwee, Karthik Ramasamy, Simon Stern, et al.. (2024). Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper. British Journal of Haematology. 204(4). 1193–1206. 1 indexed citations

Xu, Ke, Nikolaos Kanellias, William Wilson, et al.. (2024). Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single center, real-world experience. Haematologica. 110(5). 1182–1186.

Wilson, William, Rakesh Popat, Ke Xu, et al.. (2024). Outcomes of melphalan 140 mg/m² followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience. SHILAP Revista de lepidopterología. 5(5). 1102–1106.

Xu, Ke, Elisabeth P. Nacheva, Annabel McMillan, et al.. (2024). Myeloid neoplasm post cytotoxic treatment in patients with multiple myeloma. SHILAP Revista de lepidopterología. 5(5). 1089–1091.

Yong, Kwee, Annabel McMillan, Xenofon Papanikolaou, et al.. (2023). The Impact of Continuous Lenalidomide Maintenance Treatment on People Living with Multiple Myeloma - a Single-Centre Qualitative Service Evaluation. Blood. 142(Supplement 1). 6640–6640.

McCourt, Orla, Abigail Fisher, Gita Ramdharry, et al.. (2023). Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT pilot randomised controlled trial. Acta Oncologica. 62(7). 696–705. 15 indexed citations

Wilson, William, Christopher Parrish, Gabriel Wallis, et al.. (2021). Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma. Frontiers in Oncology. 11. 703233–703233. 12 indexed citations

Cohen, Oliver C., Faye Sharpley, Julian D. Gillmore, et al.. (2020). Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis. British Journal of Haematology. 189(4). 643–649. 28 indexed citations

Bird, Sarah, Charlotte Pawlyn, Priya Sriskandarajah, et al.. (2020). A real‐world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple‐myeloma patients. British Journal of Haematology. 191(5). 927–930. 7 indexed citations

10.

McCourt, Orla, Abigail Fisher, Gita Ramdharry, et al.. (2020). PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma. BMJ Open. 10(1). e033176–e033176. 18 indexed citations

11.

Yong, Kwee, et al.. (2020). Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma. Hematology/Oncology and Stem Cell Therapy. 14(2). 160–162. 4 indexed citations

12.

Manwani, Richa, Shameem Mahmood, Sajitha Sachchithanantham, et al.. (2019). Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. British Journal of Haematology. 187(5). 638–641. 36 indexed citations

13.

Kyriakou, Charalampia, et al.. (2017). REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA. UCL Discovery (University College London). 5 indexed citations

14.

Latifoltojar, Arash, Margaret Hall‐Craggs, Alan Bainbridge, et al.. (2017). Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. European Radiology. 27(12). 5325–5336. 59 indexed citations

15.

Latifoltojar, Arash, Margaret Hall‐Craggs, Neil Rabin, et al.. (2016). Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. British Journal of Haematology. 176(2). 222–233. 46 indexed citations

16.

Dimopoulos, Meletios Α., Albert Oriol, Hareth Nahi, et al.. (2016). An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX. 101. 11 indexed citations

17.

Melville, Andrew, Paul Maciocia, Faye Sharpley, et al.. (2016). Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience. Blood. 128(22). 3312–3312. 1 indexed citations

18.

Kassen, Deepika, Darren Lath, Holly Evans, et al.. (2015). Myeloma impairs mature osteoblast function but causes early expansion of osteo‐progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. British Journal of Haematology. 172(1). 64–79. 15 indexed citations

19.

Maciocia, Paul, Nicholas Counsell, A G Bird, et al.. (2013). Single Centre Analysis Of Autologous Stem Cell Transplant Outcomes In Multiple Myeloma In 338 Consecutive Patients: Maintenance/Consolidation Is Associated With Superior Survival, But Early Relapse Is The Single Most Important Predictor Of Survival and May Override Genetic Risk. Blood. 122(21). 2159–2159. 1 indexed citations

20.

Kyriakou, Chara, Neil Rabin, Arnold Pizzey, Amit Nathwani, & Kwee Yong. (2008). Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model. Haematologica. 93(10). 1457–1465. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact